Discover how the RAD conference in Nashville enhances atopic dermatitis care, featuring expert insights and patient-focused strategies for clinicians.

Discover how upadacitinib outperforms dupilumab in providing rapid itch relief for moderate-to-severe atopic dermatitis in a recent AAD study.

Dermatology undergoes rapid transformation with new therapies, but faces challenges in payment reform, certification awareness, and balancing technology with patient care.

Paller discusses the promising phase 3 trial SELVA trial results for Qtorin 3.9% rapamycin gel, an investigative treatment for microcystic lymphatic malformations.

From our April issue: Unlock exclusive AAD 2025 insights from top dermatology experts—what you missed and what’s next.

Raj Chovatiya, MD, PhD, MSCI, reviews the benefits of Revolutionizing Atopic Dermatitis as a disease-specific conference.

Tapinarof offers sustained relief for atopic dermatitis, enabling treatment-free periods and long-term disease control—even in young children.

A new subgroup analysis revealed higher rates of clear or almost clear skin at week 16 vs placebo with a favorable safety profile.

Get a glimpse of the cutting-edge atopic dermatitis research, breakthroughs, and insights to be presented at the 7th RAD Annual Meeting, June 6-7, 2025.

Dermatology Times has compiled a list of dermatological meetings taking place during the month of April.

Asha Patel Shah, MD, MBA, FAAD, discusses recent research on retinol and retinoid bioactivity when layered with moisturizers highlighted at AAD 2025.

Discover the latest research from the AAD poster hall, compiled in one place for dermatology professionals.

Explore a comprehensive roundup of the most important AAD late breakers, all in one place – key insights from the latest dermatology research.

Christopher B. Zachary, MBBS, MRCP, FRCP, shares insights in apoptosis-based skin care treatment.

Catch up on all coverage from the 2025 American Academy of Dermatology Annual Meeting held in Orlando, Florida, March 7-11.

Christopher Bunick, MD, PhD, shares concluding remarks with colleagues at AAD 2025.

Karl Yen of Sanofi discussed the role of amlitelimab in AD following sustained results and a promising safety profile presented in data at AAD.

Novartis highlighted key findings at AAD and AAAAI, showcasing Cosentyx's flexible dosing for hidradenitis suppurativa and remibrutinib’s efficacy for chronic spontaneous urticaria.

Elizabeth Berry, MD, FAAD, reviewed dysplastic nevi as risk markers and highlighted the need for more data on severe cases at AAD 2025.

Li discusses microneedling innovations, global techniques, safety, and future trends in dermatology, including integration with RF and PRP.